Abstract
Recently, a lot of new anti-cancer agents have come to the cancer treatment scene. The development of monoclonal antibodies like rituximab, trastuzumab, cetuximab, and bevacizumab are symbolic of the new era, and their effect on the various cancers is remarkable. They have occupied essential position in the cancer treatment as a first-line therapy or as an adjuvant therapy.
In Japan, the approval of drugs which are not only anti-cancer agent but also any other drugs don't have been quick for long ago. So when we treat the cancer patient with their new agent, there is the limitation in the way to use them. But we should not only submit to this situation, as a member of worker in Japanese medical academic, clinical, industrial situation should progress the research and development and clinical study of the new anti-cancer agent including monoclonal antibody.
